Logo image of MXCT

MAXCYTE INC (MXCT) Stock Fundamental Analysis

NASDAQ:MXCT - US57777K1060 - Common Stock

1.39 USD
0 (0%)
Last: 8/29/2025, 8:00:01 PM
1.3973 USD
+0.01 (+0.53%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, MXCT scores 3 out of 10 in our fundamental rating. MXCT was compared to 54 industry peers in the Life Sciences Tools & Services industry. MXCT has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, MXCT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MXCT has reported negative net income.
In the past year MXCT has reported a negative cash flow from operations.
In the past 5 years MXCT always reported negative net income.
In the past 5 years MXCT always reported negative operating cash flow.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.37%, MXCT is doing worse than 62.96% of the companies in the same industry.
The Return On Equity of MXCT (-23.47%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROIC N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

MXCT has a Gross Margin of 79.79%. This is amongst the best in the industry. MXCT outperforms 100.00% of its industry peers.
In the last couple of years the Gross Margin of MXCT has declined.
MXCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MXCT has been increased compared to 1 year ago.
MXCT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 1.63, we must say that MXCT is in the distress zone and has some risk of bankruptcy.
MXCT has a Altman-Z score (1.63) which is in line with its industry peers.
MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.63
ROIC/WACCN/A
WACC10.51%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

MXCT has a Current Ratio of 12.39. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MXCT (12.39) is better than 94.44% of its industry peers.
MXCT has a Quick Ratio of 11.71. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
MXCT has a better Quick ratio (11.71) than 94.44% of its industry peers.
Industry RankSector Rank
Current Ratio 12.39
Quick Ratio 11.71
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for MXCT have decreased strongly by -26.47% in the last year.
Looking at the last year, MXCT shows a very negative growth in Revenue. The Revenue has decreased by -21.31% in the last year.
MXCT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.31% yearly.
EPS 1Y (TTM)-26.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-21.31%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-18.43%

3.2 Future

Based on estimates for the next years, MXCT will show a decrease in Earnings Per Share. The EPS will decrease by -0.66% on average per year.
MXCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.61% yearly.
EPS Next Y-10.72%
EPS Next 2Y-5.43%
EPS Next 3Y-0.66%
EPS Next 5YN/A
Revenue Next Year-3.89%
Revenue Next 2Y5.04%
Revenue Next 3Y10.54%
Revenue Next 5Y28.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MXCT. In the last year negative earnings were reported.
Also next year MXCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.43%
EPS Next 3Y-0.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MXCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAXCYTE INC

NASDAQ:MXCT (8/29/2025, 8:00:01 PM)

After market: 1.3973 +0.01 (+0.53%)

1.39

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners67.27%
Inst Owner Change-0.36%
Ins Owners1.05%
Ins Owner Change5.35%
Market Cap148.19M
Analysts88.33
Price Target6.47 (365.47%)
Short Float %3.54%
Short Ratio4.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.61%
Min EPS beat(2)-13.86%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)6.24%
Min EPS beat(4)-13.86%
Max EPS beat(4)19.64%
EPS beat(8)6
Avg EPS beat(8)14.2%
EPS beat(12)9
Avg EPS beat(12)14.45%
EPS beat(16)13
Avg EPS beat(16)16.81%
Revenue beat(2)1
Avg Revenue beat(2)-3.6%
Min Revenue beat(2)-12.47%
Max Revenue beat(2)5.28%
Revenue beat(4)3
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-12.47%
Max Revenue beat(4)8.53%
Revenue beat(8)6
Avg Revenue beat(8)11.35%
Revenue beat(12)8
Avg Revenue beat(12)5.7%
Revenue beat(16)12
Avg Revenue beat(16)9.06%
PT rev (1m)-9.37%
PT rev (3m)-13.49%
EPS NQ rev (1m)-21.28%
EPS NQ rev (3m)-18.75%
EPS NY rev (1m)-11.4%
EPS NY rev (3m)-11.4%
Revenue NQ rev (1m)-19.24%
Revenue NQ rev (3m)-29.64%
Revenue NY rev (1m)-11.67%
Revenue NY rev (3m)-11.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.14
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.34
BVpS1.79
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.79%
FCFM N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.44%
Cap/Sales 5.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.39
Quick Ratio 11.71
Altman-Z 1.63
F-Score2
WACC10.51%
ROIC/WACCN/A
Cap/Depr(3y)270.47%
Cap/Depr(5y)255.66%
Cap/Sales(3y)18.33%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y-10.72%
EPS Next 2Y-5.43%
EPS Next 3Y-0.66%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.31%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-18.43%
Revenue Next Year-3.89%
Revenue Next 2Y5.04%
Revenue Next 3Y10.54%
Revenue Next 5Y28.61%
EBIT growth 1Y-13.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.01%
OCF growth 3YN/A
OCF growth 5YN/A